Nevirapine (CAS 129618-40-2)
See product citations (5)
QUICK LINKS
Nevirapine is widely utilized in research focusing on the study of viral replication mechanisms, particularly in the context of HIV. Researchers employ Nevirapine to investigate its inhibitory effects on the reverse transcriptase enzyme, which is critical in the HIV replication process. This application is fundamental in understanding how viral resistance to inhibitors develops over time, and what strategies might be more effective in curbing viral proliferation at the molecular level. Additionally, Nevirapine serves as a tool in the study of chemical interactions and metabolic pathways in virology research labs, providing insights into how different compounds can influence the activity of enzymes involved in virus replication.
Nevirapine (CAS 129618-40-2) References
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. | Guay, LA., et al. 1999. Lancet. 354: 795-802. PMID: 10485720
- Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. | Bardsley-Elliot, A. and Perry, CM. 2000. Paediatr Drugs. 2: 373-407. PMID: 11022799
- Nevirapine: pharmacokinetic considerations in children and pregnant women. | Mirochnick, M., et al. 2000. Clin Pharmacokinet. 39: 281-93. PMID: 11069214
- The role of nevirapine in the treatment of HIV-1 disease. | Podzamczer, D. and Fumero, E. 2001. Expert Opin Pharmacother. 2: 2065-78. PMID: 11825335
- Nevirapine in the treatment of HIV. | Milinkovic, A. and Martínez, E. 2004. Expert Rev Anti Infect Ther. 2: 367-73. PMID: 15482202
- Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. | Hargrave, KD., et al. 1991. J Med Chem. 34: 2231-41. PMID: 1712395
- Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. | Cooper, CL. and van Heeswijk, RP. 2007. HIV Med. 8: 1-7. PMID: 17305925
- Is it safe to switch between efavirenz and nevirapine in the event of toxicity? | Mehta, U. and Maartens, G. 2007. Lancet Infect Dis. 7: 733-8. PMID: 17961859
- Risk for immune-mediated liver reactions by nevirapine revisited. | Medrano, J., et al. 2008. AIDS Rev. 10: 110-5. PMID: 18615121
- [Evidence-based therapeutic drug monitoring for nevirapine]. | Muret, P., et al. 2011. Therapie. 66: 187-95. PMID: 21819802
- Nevirapine modulation of paraoxonase-1 in the liver: An in vitro three-model approach. | Marinho, AT., et al. 2016. Eur J Pharm Sci. 82: 147-53. PMID: 26620700
- Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity. | Marinho, AT., et al. 2019. Drug Metab Rev. 51: 76-90. PMID: 30712401
- Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. | Cheeseman, SH., et al. 1993. Antimicrob Agents Chemother. 37: 178-82. PMID: 8452345
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nevirapine, 5 mg | sc-208092 | 5 mg | $99.00 |